Claims for Patent: 10,918,608

Summary for Patent: 10,918,608

Title:	Use of cannabidiol in the treatment of epilepsy
Abstract:	The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
Inventor(s):	Guy; Geoffrey (Cambridge, GB), Wright; Stephen (Cambridge, GB), Thiele; Elizabeth (Boston, MA)
Assignee:	GW Research Limited (Cambridge, GB)
Application Number:	14/881,954
Patent Claims:	1. A method of treating seizures in a patient suffering from Tuberous Sclerosis Complex (TSC) comprising administering cannabidiol (CBD) to the patient, wherein the CBD has a purity of at least 98% (w/w) CBD and comprises no more than 0.15% (w/w) .DELTA.9-tetrahydrocannabidiol, and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg, up to 25 mg/kg/day. 2. The method according to claim 1, wherein the TSC is treatment resistant. 3. The method according to claim 1, wherein the TSC is characterized by generalized seizures or focal seizures with impairment. 4. The method according to claim 3, wherein the generalized seizures include one or more seizure sub-types selected from the group consisting of tonic; atonic; tonic-clonic; and absence seizures. 5. The method according to claim 1, wherein the CBD is administered in combination with a therapeutic dose of one or more concomitant anti-epileptic drugs (AED). 6. The method according to claim 1, wherein the CBD is present as a synthetic compound. 7. The method according to claim 5, wherein the one or more AED is selected from the group consisting of: clobazam; diazepam; lacosamide; lamotrigine; levetiracetam; lorazepam; nordiazepam; n-desmethylclobazam; phenytoin; valproic acid; and zonisamide. 8. The method according to claim 5, wherein the number of different AED that are administered in combination with the CBD to the subject in need thereof is reduced relative to the number of AED administered prior to treatment with CBD. 9. The method according to claim 5, wherein the dose of the one or more AED that are used in combination with the CBD is reduced relative to the dose of AED administered prior to treatment with CBD. 10. The method according to claim 5, wherein the AED is clobazam. 11. The method according to claim 5, wherein the AED is valproic acid. 12. The method according to claim 1, wherein the dose of CBD is increased to 20 mg/kg/day. 13. The method according to claim 1, wherein the dose of CBD is increased to 25 mg/kg/day. 14. A method of treating generalized seizures or focal seizures with impairment in a patient suffering from Tuberous Sclerosis Complex (TSC) comprising administering cannabidiol (CBD) to the subject in need thereof, wherein the CBD has a purity of at least 98% (w/w) CBD and comprises no more than 0.15% (w/w) .DELTA.9-tetrahydrocannabidiol; and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg, up to 25 mg/kg/day. 15. The method according to claim 14, wherein the dose of CBD is increased to about 20 mg/kg/day. 16. The method according to claim 14, wherein the dose of CBD is increased to about 25 mg/kg/day. 17. A method of reducing seizure frequency in a patient suffering from Tuberous Sclerosis Complex (TSC) comprising administering cannabidiol (CBD) to the subject in need thereof, wherein the CBD has a purity of at least 98% (w/w) CBD and comprises no more than 0.15% (w/w) .DELTA.9-tetrahydrocannabidiol, and wherein the CBD is administered at a dose of 5 mg/kg/day, and then the dose is increased by 2 to 5 mg/kg, up to 25 mg/kg/day. 18. The method according to claim 17, wherein the dose of CBD is increased to 20 mg/kg/day. 19. The method according to claim 17, wherein the dose of CBD is increased to 25 mg/kg/day. 20. The method according to claim 1, wherein the dose of CBD is increased to 10 mg/kg/day. 21. The method according to claim 1, wherein the dose of CBD is increased to 15 mg/kg/day. 22. The method according to claim 14, wherein the dose of CBD is increased to 10 mg/kg/day. 23. The method according to claim 14, wherein the dose of CBD is increased to 15 mg/kg/day. 24. The method according to claim 17, wherein the dose of CBD is increased to 10 mg/kg/day. 25. The method according to claim 17, wherein the dose of CBD is increased to 15 mg/kg/day.